// App-Quantinova.ai

Sa1161 : Impact-III Demonstrates Excellent Sensitivity in Reflecting Clinical Change in the T72 Trial of Infliximab for Pediatric Ulcerative Colitis

Researchers

Presenter

  • Amy Grant

Principal Investigators

  • Jewel Johanns

  • Lakshmi Padgett

  • Marion Blank

  • Jeffrey S. Hyams

Medical Centers

  • Connecticut Children's Medical Center, Hartford, CT

  • Dalhousie University, Halifax, Nova Scotia, Canada.

  • Paediatrics, IWK Health Centre, Halifax, NS, Canada

Locations

  • United States

  • Canada

Companies

  • Janssen Global Servi

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Infliximab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved